Literature DB >> 11832307

Are all alpha-blockers created equal? An update.

Claus G Roehrborn1.   

Abstract

alpha-Receptor blockers, used to treat lower urinary tract symptoms, exert effects on areas of the body other than the prostate where alpha-receptors are located, including the blood vessels and the central nervous system. alpha-Receptors in the central and peripheral nervous system may be involved in bladder activation. alpha(1a)-Receptors are the appropriate target in men with obstructive symptoms, although alpha(1d)-receptors may also be important in patients with irritative symptoms. There is conflicting evidence about the selectivity of alpha-blockers. Clinical trials of these agents do not necessarily reflect results observed in animal and laboratory studies on uroselectivity. The few published comparator studies of alpha-blockers indicate similar efficacies, although side-effect profiles differ somewhat. Randomized, controlled studies of different alpha-blockers with sufficient power to detect differences in side effects between agents are needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832307     DOI: 10.1016/s0090-4295(01)01555-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  The Clinical Benefits of Dutasteride Treatment for LUTS and BPH.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2004

2.  Quality of life in sexually active men with symptomatic benign prostatic hyperplasia : effects of treatment.

Authors:  Mel P Daly
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 3.  The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Chris M Gonzalez; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.